CY1113875T1 - Βελτιστοποιημενη εκφραση hpv 58 l1 σε ζυμομυκητα - Google Patents

Βελτιστοποιημενη εκφραση hpv 58 l1 σε ζυμομυκητα

Info

Publication number
CY1113875T1
CY1113875T1 CY20101100258T CY101100258T CY1113875T1 CY 1113875 T1 CY1113875 T1 CY 1113875T1 CY 20101100258 T CY20101100258 T CY 20101100258T CY 101100258 T CY101100258 T CY 101100258T CY 1113875 T1 CY1113875 T1 CY 1113875T1
Authority
CY
Cyprus
Prior art keywords
hpv58
present
vaccines
protein
vlps
Prior art date
Application number
CY20101100258T
Other languages
Greek (el)
English (en)
Inventor
Janine T Bryan
Michelle K Brownlow
Loren D Schultz
Xin-Min Wang
Kathrin U Jansen
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Publication of CY1113875T1 publication Critical patent/CY1113875T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CY20101100258T 2003-11-12 2010-03-19 Βελτιστοποιημενη εκφραση hpv 58 l1 σε ζυμομυκητα CY1113875T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51921103P 2003-11-12 2003-11-12
EP04810619A EP1687329B8 (en) 2003-11-12 2004-11-10 Optimized expression of hpv 58 l1 in yeast

Publications (1)

Publication Number Publication Date
CY1113875T1 true CY1113875T1 (el) 2016-06-22

Family

ID=34590374

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20101100258T CY1113875T1 (el) 2003-11-12 2010-03-19 Βελτιστοποιημενη εκφραση hpv 58 l1 σε ζυμομυκητα
CY2015051C CY2015051I2 (el) 2003-11-12 2015-12-07 Βελτιστοποιημενη εκφραση hpv 58 l1 σε ζυμομυκητα

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2015051C CY2015051I2 (el) 2003-11-12 2015-12-07 Βελτιστοποιημενη εκφραση hpv 58 l1 σε ζυμομυκητα

Country Status (32)

Country Link
US (2) US7498036B2 (enExample)
EP (1) EP1687329B8 (enExample)
JP (2) JP4912885B2 (enExample)
KR (1) KR101170654B1 (enExample)
CN (1) CN1942583B (enExample)
AR (1) AR046835A1 (enExample)
AT (1) ATE452977T1 (enExample)
AU (1) AU2004290032B2 (enExample)
BE (1) BE2015C070I2 (enExample)
BR (1) BRPI0416393B1 (enExample)
CA (1) CA2543928C (enExample)
CY (2) CY1113875T1 (enExample)
DE (1) DE602004024821D1 (enExample)
DK (1) DK1687329T3 (enExample)
ES (1) ES2340287T3 (enExample)
FR (1) FR15C0081I2 (enExample)
HU (1) HUS1500064I1 (enExample)
IL (1) IL175353A (enExample)
IS (1) IS2741B (enExample)
LT (1) LTC1687329I2 (enExample)
LU (1) LU92901I2 (enExample)
MY (1) MY139500A (enExample)
NL (1) NL300775I1 (enExample)
NO (3) NO340633B1 (enExample)
NZ (1) NZ546697A (enExample)
PL (1) PL1687329T3 (enExample)
PT (1) PT1687329E (enExample)
RU (1) RU2370538C2 (enExample)
SI (1) SI1687329T1 (enExample)
TW (1) TWI332988B (enExample)
WO (1) WO2005047315A2 (enExample)
ZA (1) ZA200603106B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
US8206950B2 (en) * 2003-06-09 2012-06-26 Animal Technology Institute Taiwan Fusion antigen used as vaccine and method of making them
ATE466022T1 (de) 2004-03-24 2010-05-15 Merck Sharp & Dohme Optimierte expression von hpv-52-l1 in hefe
US20070243587A1 (en) * 2006-04-14 2007-10-18 Healthbanks Biotech Co., Ltd. Using a reverse genetic engineering platform to produce protein vaccines and protein vaccine of avian influenza virus
CN101148661B (zh) * 2006-09-18 2013-01-02 中国医学科学院基础医学研究所 人乳头瘤病毒16型外壳蛋白病毒样颗粒及其制备方法和用途
AU2008226974B2 (en) * 2007-03-09 2013-08-15 Merck Sharp & Dohme Llc Papillomavirus vaccine compositions
EP2154147B1 (en) 2007-04-29 2015-10-07 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. A truncated l1 protein of human papillomavirus 16
EP2147926B1 (en) 2007-04-29 2016-08-24 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated human papillomavirus type 18 l1 proteins
EP2154149B1 (en) * 2007-05-29 2019-07-10 Xiamen University A truncated l1 protein of human papillomavirus 6
CN101113417B (zh) * 2007-06-22 2011-04-27 山东大学 Hpv基因酵母体外翻译系统的建立
CN101200696B (zh) * 2007-11-14 2011-07-20 山东大学 人乳头瘤病毒的酵母增殖模型及建立方法与应用
WO2009076824A1 (zh) 2007-11-23 2009-06-25 Shanghai Zerun Biotechnology Co., Ltd. 人乳头状瘤病毒主要衣壳蛋白l1基因及其用途
KR20090073987A (ko) * 2007-12-31 2009-07-03 정운원 인간유두종바이러스 유전자형 검사를 위한 프라이머, 프로브 및 이를 포함하는 ｄｎａ칩, 이의 검사 방법 및 검사 키트
BRPI0909547A2 (pt) * 2008-05-26 2019-03-06 Cadila Healthcare Ltd. vacina combinada de sarampo - hpv, vetor e hospedero
US9335868B2 (en) * 2008-07-31 2016-05-10 Apple Inc. Capacitive sensor behind black mask
CA2799205A1 (en) 2010-05-25 2011-12-01 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically-truncated probes
CN101857870B (zh) * 2010-06-12 2012-09-05 上海泽润生物科技有限公司 Hpv58 l1基因及载体、菌株和表达方法
EP2594579B1 (en) * 2010-07-16 2015-04-15 Xiamen University Truncated human papillomavirus type 58 l1 protein
CN102154325B (zh) * 2011-01-01 2013-08-21 上海生物制品研究所有限责任公司 针对人乳头瘤状病毒的疫苗及其制法和用途
CN103717741B (zh) * 2011-06-15 2016-04-13 中央大学校产学协力团 用于提高人乳头瘤病毒l1蛋白产量的方法
CN103361280B (zh) * 2012-03-28 2018-07-24 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv11 l1蛋白的方法
AU2013272283B2 (en) 2012-06-07 2018-02-15 The Children's Hospital Of Philadelphia Controlled gene expression methods
CN103992395B (zh) * 2013-02-18 2018-07-27 北京康乐卫士生物技术股份有限公司 重组hpv-58型l1的vlp疫苗及其制备方法
CN110423774A (zh) * 2013-04-26 2019-11-08 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv58 l1蛋白的方法
CN104164374B (zh) * 2013-05-17 2019-10-22 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv31 l1蛋白的方法
CN104164373B (zh) * 2013-05-17 2019-04-02 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv68l1蛋白的方法
WO2015057541A1 (en) 2013-10-16 2015-04-23 Merck Sharp & Dohme Corp. Method of obtaining thermostable dried vaccine formulations
EP3191505A2 (en) * 2014-09-11 2017-07-19 Cadila Healthcare Limited Superior human papilloma virus antigens with superior immunological properties and vaccine containing it
CN106148359A (zh) * 2015-03-30 2016-11-23 上海泽润生物科技有限公司 重组人乳头瘤病毒33亚型蛋白表达
CN104878022A (zh) * 2015-04-27 2015-09-02 段青姣 编码hpv58l1、hpv52l1蛋白的核苷酸序列及其应用
EP3385273A4 (en) * 2015-12-04 2019-08-07 Xiamen University MUTANT OF HUMAN PAPILLOMAIRUS TYPE 58 L1 PROTEIN
US12673103B2 (en) 2020-02-14 2026-07-07 Merck Sharp & Dohme Llc HPV vaccine
CN113073105B (zh) * 2021-03-23 2023-06-13 重庆博唯佰泰生物制药有限公司 一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用
CN113549634B (zh) * 2021-06-07 2023-03-31 郑州大学 编码可溶性hpv58 l1蛋白的基因及其重组质粒的构建与应用
WO2023014853A1 (en) 2021-08-06 2023-02-09 Merck Sharp & Dohme Llc Hpv vaccine
AR126813A1 (es) 2021-08-19 2023-11-15 Merck Sharp & Dohme Llc Nueva nanopartícula lipídica termostable y métodos de uso de la misma
CR20250529A (es) 2023-06-09 2026-01-12 Merck Sharp & Dohme Llc Composiciones adyuvantes en nanoemulsión para vacunas contra el papilomavirus humano
CN117054647A (zh) * 2023-07-17 2023-11-14 广东省一鼎生物技术有限公司 一种检测HPV IgG抗体试剂盒及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821087A (en) 1995-03-30 1998-10-13 Merck & Co., Inc. Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
IL117591A0 (en) 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
EE9900343A (et) 1997-02-07 2000-02-15 Merck & Co., Inc. Sünteetiline polünukleotiid, immuunvastuste tekitamise meetod, immunogeenne kompositsioon, anti-HIV immuunvastuste indutseerimise meetod, meetod antigeeni tekitava raku indutseerimiseks ja farmatseutiline kompositsioon
CA2296067C (en) 1997-07-09 2008-10-07 The University Of Queensland Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue
EP1105466B1 (en) * 1998-08-14 2006-04-26 Merck & Co., Inc. Process for purifying human papillomavirus virus-like particles
DE69933875T2 (de) 1998-08-14 2007-05-31 Merck & Co., Inc. Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt.
SE514982C2 (sv) * 1999-09-30 2001-05-28 Active Biotech Ab Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning
ES2233437T3 (es) * 1999-08-25 2005-06-16 MERCK & CO., INC. Genes sinteticos del papilomavirus optimizados para expresion en celulas humanas.
US6436402B1 (en) * 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
NZ523683A (en) 2000-07-21 2004-08-27 Glaxo Group Ltd Codon-optimized papilloma virus sequences
WO2003068804A2 (en) * 2002-02-14 2003-08-21 Novavax, Inc. Novel insect cell line
RU2356943C2 (ru) * 2003-03-24 2009-05-27 Мерк Энд Ко., Инк. Молекула нуклеиновой кислоты, кодирующая hpv31 l1, экспрессирующий вектор, клетка-хозяин, вирусоподобная частица и способ ее получения, вакцина, фармацевтическая композиция и способы с их использованием
MY140664A (en) 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast

Also Published As

Publication number Publication date
US7976848B2 (en) 2011-07-12
JP5616879B2 (ja) 2014-10-29
CY2015051I1 (el) 2016-06-22
NZ546697A (en) 2009-05-31
NL300775I2 (enExample) 2015-12-29
CA2543928C (en) 2011-04-05
JP2008500019A (ja) 2008-01-10
KR20060122852A (ko) 2006-11-30
EP1687329B1 (en) 2009-12-23
KR101170654B1 (ko) 2012-08-03
CY2015051I2 (el) 2016-06-22
IL175353A (en) 2010-11-30
US20070036824A1 (en) 2007-02-15
IS2741B (is) 2011-06-15
TWI332988B (en) 2010-11-11
BRPI0416393B1 (pt) 2021-06-29
FR15C0081I1 (fr) 2016-08-01
LTC1687329I2 (lt) 2017-05-10
PT1687329E (pt) 2010-02-26
JP2012095652A (ja) 2012-05-24
NO2022052I1 (no) 2022-11-30
RU2006120402A (ru) 2007-12-27
TW200519203A (en) 2005-06-16
WO2005047315A2 (en) 2005-05-26
BE2015C070I2 (enExample) 2023-12-18
IS8425A (is) 2006-04-21
IL175353A0 (en) 2006-09-05
US20100272749A1 (en) 2010-10-28
MY139500A (en) 2009-10-30
SI1687329T1 (sl) 2010-03-31
LU92901I2 (fr) 2016-03-08
HUS1500064I1 (hu) 2016-02-29
AR046835A1 (es) 2005-12-28
ES2340287T3 (es) 2010-06-01
WO2005047315A3 (en) 2006-09-28
NO20062674L (no) 2006-06-09
DE602004024821D1 (de) 2010-02-04
NO340633B1 (no) 2017-05-15
CN1942583A (zh) 2007-04-04
ZA200603106B (en) 2007-09-26
CN1942583B (zh) 2010-10-27
AU2004290032B2 (en) 2009-02-05
DK1687329T3 (da) 2010-04-12
RU2370538C2 (ru) 2009-10-20
PL1687329T3 (pl) 2010-06-30
FR15C0081I2 (fr) 2016-11-25
CA2543928A1 (en) 2005-05-26
EP1687329A2 (en) 2006-08-09
NO2017058I1 (no) 2017-11-10
EP1687329B8 (en) 2010-03-17
ATE452977T1 (de) 2010-01-15
BRPI0416393A (pt) 2007-04-03
AU2004290032A1 (en) 2005-05-26
NL300775I1 (enExample) 2015-12-29
JP4912885B2 (ja) 2012-04-11
US7498036B2 (en) 2009-03-03

Similar Documents

Publication Publication Date Title
CY1110525T1 (el) Βελτιστοποιημενη εκφραση της hpv 45 li σε ζυμη
MY139500A (en) Optimized expression of hpv 58 l1 in yeast
NO2018010I1 (no) HPV 31 L1 protein
CY1110349T1 (el) Βελτιστοποιημενη εκφραση toy hpv 52 l1 σε ζυμη
CY1110585T1 (el) ΣΥΣΚΕΥΑΣΙΑ (ΠΑΚΕΤΑΡΙΣΜΑ) ΑΝΟΣΟΔΙΕΓΕΡΤIΚΩΝ CpG ΕΝΤΟΣ ΟΜΟΙΑΖΟΝΤΩΝ ΜΕ ΙΟ ΣΩΜΑΤΙΩΝ: ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΚΑΙ ΧΡΗΣΗ
SI1685243T1 (sl) Imortalizirane ptičje celične linije za produkcijo virusov
SG131116A1 (en) Functional influenza virus-like particles (vlps)
DK1292328T3 (da) Kimære humant papillomvirus- (HPV) - molekyler og deres anvendelse
BRPI0412845A (pt) herpes-vìrus, uso de um vìrus, composição farmacêutica, e, método de tratamento de um tumor em um indivìduo em necessidade do mesmo
CY1105555T1 (el) Ανθρωπινα πολυπεπτιδια pellino
AR041515A1 (es) Vacuna a dna contra el virus de papiloma humano
NO20081541L (no) Ny sjo-lus vaksine
ATE450546T1 (de) Impfstoffe mit ornithobakterium rhinotracheale- untereinheit